ClinicalTrials.gg
CompletedNCT05574374Updated Apr 4, 2023

Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects

A Phase 1 interventional study of DWP14012 and DWC202202 in Drug Drug Interaction, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects

02

Conditions studied

  • Drug Drug Interaction
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged ≥ 19 and ≤ 50 years at screening
  • Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening

    ※ BMI (kg/m2) = body weight (kg)/[height (m)]2

  • Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information
  • Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history related to blood clotting disorder or bleeding
  • Subjects with or history of hypersensitivity to drugs including potassium competitive acid blocker [P-CAB] class, aspirin, antibiotics, etc.
  • Subjects with a history of drug abuse or a positive result of using abusive drugs in the urine drug screen
  • Subjects who participated in other clinical trials (including bioequivalence studies) within 6 months prior to the first scheduled dose of the IP
  • Subjects who donated whole blood within 2 months, donated blood components within 1 month, or received blood transfusion within 1 month prior to the first scheduled dose
  • Subjects who are unable to refrain from grapefruit-containing products from 3 days prior to the first scheduled dose until last discharge from hospital
  • Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc.
  • Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration
  • Subjects who are smoking
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1

    * Treatment A: DWC202202 1 tablet qd for 7days * Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days * Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days

    Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203

  • Experimental
    Cohort 2

    * Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days * Treatment A: DWC202202 1 tablet qd for 7days * Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days

    Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203

  • Experimental
    Cohort 3

    * Treatment B: DWC202202 1 tablet qd + DWP14012 1 tablet qd for 7days * Treatment C: DWC202202 1 tablet qd + DWC202203 1 tablet qd for 7days * Treatment A: DWC202202 1 tablet qd for 7days

    Drug: DWP14012 · Drug: DWC202202 · Drug: DWC202203

Interventions

  • Potassium-competitive acid blocker

  • DrugDWC202202

    Clopidogrel Bisulfate

  • DrugDWC202203

    Proton pump inhibitor

06

What researchers measure

Primary outcomes

  1. Emax

    Time frame: up to 50 days

  2. AUEC0-24

    Time frame: up to 50 days

Secondary outcomes

  1. DWC202202 Cmax,ss

    Time frame: up to 50 days

  2. DWC202202 active metabolite Cmax,ss

    Time frame: up to 50 days

  3. DWC202202 AUCtau,ss

    Time frame: up to 50 days

  4. DWC202202 active metabolite AUCtau,ss

    Time frame: up to 50 days

  5. DWC202202 AUCinf,ss

    Time frame: up to 50 days

  6. DWC202202 active metabolite AUCinf,ss

    Time frame: up to 50 days

  7. DWC202202 Tmax,ss

    Time frame: up to 50 days

  8. DWC202202 active metabolite Tmax,ss

    Time frame: up to 50 days

  9. DWC202202 t1/2,ss

    Time frame: up to 50 days

  10. DWC202202 active metabolite t1/2,ss

    Time frame: up to 50 days

  11. DWC202202 Cmin,ss

    Time frame: up to 50 days

  12. DWC202202 active metabolite Cmin,ss

    Time frame: up to 50 days

  13. DWC202202 Cavg,ss

    Time frame: up to 50 days

  14. DWC202202 active metabolite Cavg,ss

    Time frame: up to 50 days

  15. DWC202202 CLss/F

    Time frame: up to 50 days

  16. DWC202202 Vd,ss/F

    Time frame: up to 50 days

  17. DWC202202 PTF (peak to trough fluctuation)

    Time frame: up to 50 days

  18. DWC202202 active metabolite PTF (peak to trough fluctuation)

    Time frame: up to 50 days

  19. DWC202202 R

    Time frame: up to 50 days

  20. DWC202202 active metabolite MR

    Time frame: up to 50 days

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Mar 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Oct 10, 2022
StartActual
Sep 21, 2022
Primary completionActual
Mar 6, 2023
CompletionActual
Mar 6, 2023
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05574374
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Sep 21, 2022
Primary completion
Mar 6, 2023
Completion
Mar 6, 2023
Last update
Apr 4, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion